Your browser doesn't support javascript.
loading
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.
Hata, Aaron N; Yeo, Alan; Faber, Anthony C; Lifshits, Eugene; Chen, Zhao; Cheng, Katherine A; Walton, Zandra; Sarosiek, Kristopher A; Letai, Anthony; Heist, Rebecca S; Mino-Kenudson, Mari; Wong, Kwok-Kin; Engelman, Jeffrey A.
Afiliação
  • Hata AN; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, MassachusettsAuthors' Affiliations: Mas
  • Yeo A; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Faber AC; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Lifshits E; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Chen Z; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, MassachusettsAuthors' Affiliations: Mas
  • Cheng KA; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Walton Z; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Sarosiek KA; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Letai A; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Heist RS; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, MassachusettsAuthors' Affiliations: Mas
  • Mino-Kenudson M; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Wong KK; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, MassachusettsAuthors' Affiliations: Mas
  • Engelman JA; Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, MassachusettsAuthors' Affiliations: Mas
Cancer Res ; 74(11): 3146-56, 2014 Jun 01.
Article em En | MEDLINE | ID: mdl-24675361
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Apoptose / Proteínas ras / Proteínas Proto-Oncogênicas c-bcl-2 / Sistema de Sinalização das MAP Quinases / Inibidores de Proteínas Quinases / Inibidores de Fosfoinositídeo-3 Quinase / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Apoptose / Proteínas ras / Proteínas Proto-Oncogênicas c-bcl-2 / Sistema de Sinalização das MAP Quinases / Inibidores de Proteínas Quinases / Inibidores de Fosfoinositídeo-3 Quinase / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos